T-Cell Therapy for Advanced Prostate Cancer with Bone Spread
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new type of immune cell therapy (gamma delta T cells) targeted at a marker on prostate cancer cells to see if it can shrink bone metastases in advanced, castration-resistant prostate cancer. It’s for men who have already tried chemotherapy and newer hormone therapies and whose cancer is getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer has spread to your bones and is getting worse
- You have already tried chemotherapy and at least one newer hormone therapy (like abiraterone or enzalutamide)
- You need to be on a bone-strengthening medicine (zoledronic acid) either already or start taking it before the treatment
- You have not had any other cancer treatment (like chemo, radiation, or immunotherapy) for at least 3 weeks before the T-cell infusion, and no radium or Pluvicto in the past 3 months
- Your heart, kidney, liver, and blood counts are in good enough shape, and you do not have serious heart disease, active infections, or other major health issues
- You must be willing to use effective birth control if you could father a child
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight advanced prostate cancer that has stopped responding to hormone treatments. The cells are engineered to recognize and attack cancer cells that have specific markers (PSMA and PSCA) on their surface.
This trial tests a new cell therapy (AZD0754) for metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It’s looking for people whose cancer has gotten worse despite prior treatments, and who are still in fairly good health.
This study tests a new type of treatment that uses your own immune cells (engineered to target prostate cancer) combined with a hormone therapy drug. It is for men with advanced prostate cancer that has stopped responding to standard hormone treatments.
This trial tests BPX-601, a new type of cell therapy that uses your own immune cells to fight prostate cancer that has spread and stopped responding to hormone treatments. The study aims to see if this approach can help men whose cancer has returned despite multiple prior treatments.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.